GDF-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR Program

被引：0
|
作者：
Ferreira, J. P. [1 ]
Sumin, M. [2 ]
Masson, S. [3 ]
Zannad, F. [1 ]
机构：
[1] Univ Lorraine, Nancy, France
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[3] Roche Diagnost Int Ltd, Rotkreuz, Switzerland
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：292 / 292
页数：1
相关论文
共 50 条
  • [41] Effectiveness of empagliflozin in patients with heart failure and COPD: Results from EMPEROR-Preserved and EMPEROR-Reduced
    Von Haehling, S.
    Butler, J.
    Anker, S. D.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [42] Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black vs White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program
    Verma, Subodh
    CIRCULATION, 2022, 146 (25) : E598 - E599
  • [43] Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
    Bernadet T. Santema
    Michelle M. Y. Chan
    Jasper Tromp
    Martin Dokter
    Haye H. van der Wal
    Johanna E. Emmens
    Janny Takens
    Nilesh J. Samani
    Leong L. Ng
    Chim C. Lang
    Peter van der Meer
    Jozine M. ter Maaten
    Kevin Damman
    Kenneth Dickstein
    John G. Cleland
    Faiez Zannad
    Stefan D. Anker
    Marco Metra
    Pim van der Harst
    Rudolf A. de Boer
    Dirk J. van Veldhuisen
    Michiel Rienstra
    Carolyn S. P. Lam
    Adriaan A. Voors
    Clinical Research in Cardiology, 2021, 110 : 1351 - 1351
  • [44] Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure
    Kuster, Nils
    Huet, Fabien
    Dupuy, Anne-Marie
    Akodad, Mariama
    Battistella, Pascal
    Agullo, Audrey
    Leclercq, Florence
    Kalmanovich, Eran
    Meilhac, Alexandra
    Aguilhon, Sylvain
    Cristol, Jean-Paul
    Roubille, Francois
    ESC HEART FAILURE, 2020, 7 (05): : 2230 - 2239
  • [45] Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
    Packer, Milton
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Schnaidt, Sven
    Zeller, Cordula
    Schnee, Janet M.
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (16) : 1284 - 1294
  • [46] Elevated GDF-15 levels may indicate malnutrition in chronic compensated heart failure with or without diabetes mellitus
    Xie, S.
    Lui, L. T.
    Ma, R. C. W.
    Graham, C. A.
    Chan, P. K. S.
    Chan, F. K. L.
    Fung, E.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1169 - 1169
  • [47] Combined Use of GDF-15 and NT-Pro BNP for Outcome Prediction in Patients with Acute Heart Failure
    Plonka, Joanna
    Klus, Anna
    Wezyk, Natalia
    Dabrowska, Klaudia
    Rzepiela, Lidia
    Gawrylak-Dryja, Ewa
    Nalewajko, Krzysztof
    Feusette, Piotr
    Gierlotka, Marek
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
  • [48] EMPEROR: Empagliflozin effects disappear after discontinuation of treatment in heart failure
    Dahm, Johannes B.
    AKTUELLE KARDIOLOGIE, 2024, 13 (01) : 22 - 22
  • [49] GDF-15 augments BNP-based risk prediction in patients with chronic systolic heart failure and kidney disease
    Benes, J.
    Kotrc, M.
    Wohlfahrt, P.
    Conrad, M. J.
    Franekova, J.
    Jabor, A.
    Lupinek, R.
    Kautzner, J.
    Melenovsky, V.
    Jarolim, P.
    EUROPEAN HEART JOURNAL, 2017, 38 : 704 - 704
  • [50] Growth differentiation factor 15 (GDF-15) is a strong predictor of outcome in heart failure patients with anaemia-results from the RED-HF study
    Ueland, T.
    Gullestad, L.
    Young, J.
    Pfeffer, M.
    Swedberg, K.
    McMurray, J. J. V.
    Diaz, R.
    Desai, A.
    Anand, I.
    Aukrust, P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1175 - 1175
12345